Prof. Dr. Eugen Leo
Eugen is Chief Medical Officer at T-knife. He has over 20 years of experience in Phase I and II development of targeted molecules (kinase inhibitors, antibodies, antibody derivatives, vaccines, and antisense molecules) with a strong focus on immuno-oncology. Previously, he held CMO/Medical Lead positions in biotech (e.g. Rigontec (acquired by Merck Inc. in 2017) and Micromet (acquired by Amgen in 2012)) and large pharmaceutical companies (Merck-Serono, Johnson&Johnson). He is a board-certified Hematologist, Medical Oncologist and Associate Professor of Medicine and did his postdoc/research fellowship at the Sanford-Burnham-Prebys Institute, La Jolla, CA (USA). He studied Medicine at Freiburg University and holds an MBA from Colorado State University (USA) and currently also serves as CMO of Catalym/Munich.